Similar to other monogenic cancers that contain a single-driver mutation (e.g., chronic myelogenous leukemia, gastrointestinal stromal tumor, etc.), targeting the TAZ–CAMTA1-driver oncoprotein either directly or indirectly will likely result in a profound clinical effect [93,94,95,96]. The gene discussed is CAMTA1; the disease is cancer.